Among the tumor types, CXCL12 expression was detected in cases of thyroid carcinoma (7/10), renal cell carcinoma (7/10), intestinal adenocarcinoma (3/5), prostate adenocarcinoma (5/10), hepatocellular carcinoma (2/5), mammary gland carcinoma (2/5), lung adenocarcinoma (3/10) and transitional cell carcinoma (2/10) (Table 1). This evidence concerns the gene CXCL12 and prostate adenocarcinoma.